Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.

Chu AY, Guilianini F, Barratt BJ, Nyberg F, Chasman DI, Ridker PM.

Circ Cardiovasc Genet. 2012 Feb 1;5(1):58-65. doi: 10.1161/CIRCGENETICS.111.961847. Epub 2012 Jan 9.

2.

Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM.

Circ Cardiovasc Genet. 2012 Apr 1;5(2):257-64. doi: 10.1161/CIRCGENETICS.111.961144. Epub 2012 Feb 13. Erratum in: Circ Cardiovasc Genet. 2012 Jun;5(3):e27.

4.

Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.

Ridker PM, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group.

Am J Cardiol. 2007 Dec 1;100(11):1659-64. Epub 2007 Oct 24.

5.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

6.

Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis.

McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, Lindberg M, Waagstein F, Grande P, Hradec J, Kamenský G, Korewicki J, Kuusi T, Mach F, Ranjith N, Wikstrand J; CORONA Study Group.

Circulation. 2009 Dec 1;120(22):2188-96. doi: 10.1161/CIRCULATIONAHA.109.849117. Epub 2009 Nov 16. Erratum in: Circulation. 2010 Jun 29;121(25):e461.

7.
8.

Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.

Ridker PM, MacFadyen JG, Glynn RJ, Chasman DI.

Circ Cardiovasc Genet. 2011 Jun;4(3):312-7. doi: 10.1161/CIRCGENETICS.110.959353. Epub 2011 Apr 14.

9.
10.

Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.

Stewart RA.

Future Cardiol. 2009 May;5(3):231-6. doi: 10.2217/fca.09.8.

PMID:
19656039
11.

C-reactive protein lowering with rosuvastatin in the METEOR study.

Peters SA, Palmer MK, Grobbee DE, Crouse JR 3rd, O'Leary DH, Raichlen JS, Bots ML.

J Intern Med. 2010 Aug;268(2):155-61. doi: 10.1111/j.1365-2796.2010.02230.x. Epub 2010 Mar 6.

12.

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial.

Awan Z, Seidah NG, MacFadyen JG, Benjannet S, Chasman DI, Ridker PM, Genest J.

Clin Chem. 2012 Jan;58(1):183-9. doi: 10.1373/clinchem.2011.172932. Epub 2011 Nov 7.

13.

Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe.

Yamazaki D, Ishida M, Watanabe H, Nobori K, Oguma Y, Terata Y, Koyama T, Iino K, Kosaka T, Ito H.

Lipids Health Dis. 2013 Feb 4;12:9. doi: 10.1186/1476-511X-12-9.

14.

The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).

O'Keefe JH, Carter MD, Lavie CJ, Bell DS.

Postgrad Med. 2009 May;121(3):113-8. doi: 10.3810/pgm.2009.05.2010. Review.

PMID:
19491548
15.

Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.

Chu AY, Guilianini F, Grallert H, Dupuis J, Ballantyne CM, Barratt BJ, Nyberg F, Chasman DI, Ridker PM.

Circ Cardiovasc Genet. 2012 Dec;5(6):676-85. doi: 10.1161/CIRCGENETICS.112.963314. Epub 2012 Nov 1.

16.

The JUPITER trial: How will it change clinical practice?

Watson KE.

Rev Cardiovasc Med. 2009 Spring;10(2):91-6. Review.

PMID:
19593321
17.

The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?

Sgueglia GA, Crea F.

J Cardiovasc Med (Hagerstown). 2011 Jan;12(1):66-70. doi: 10.2459/JCM.0b013e32834102ab.

PMID:
21139510
18.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group.

Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.

PMID:
19329177
20.
Items per page

Supplemental Content

Write to the Help Desk